May 10, 2023 / 11:20PM GMT
Jason Matthew Gerberry - BofA Securities, Research Division - MD in US Equity Research
Going with our next company presenter, and thanks for joining us at the BofA Annual Health Care Conference. My name is Jason Gerberry, I'm one of the biotech analysts at BofA. And I'm pleased to be introducing Xenon Pharmaceuticals, and we've got CEO, Ian Mortimer; and CFO, Sherry Aulin. So both of you guys, thanks for joining us. And we want to jump right into Q&A or do you have any prepared comments you want to make ahead of the -- start of that?
Ian C. Mortimer - Xenon Pharmaceuticals Inc. - President, CEO & Director
Well, one, thanks for having us. We don't have any prepared remarks, but I can give maybe a quick introduction to make sure we all have the same information and then let's jump into Q&A as well. So I think many people know Xenon well. We're a neurology company, really focused on drug and ion channels in the CNS, been doing this for more than 15 years. Lead program, which we'll focus on is XEN1101. This is a potassium channel modulator in a broad and
Xenon Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers